Medical, FDA & Affiliate Disclaimers

1. FDA Regulatory Disclosure on Compounded GLP-1 Medications

Compounded drugs (including compounded semaglutide, tirzepatide, or other GLP-1/GIP receptor agonists) are prepared by state-licensed compounding pharmacies pursuant to a prescription issued by a licensed healthcare provider in accordance with federal law under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act).

Compounded medications are not reviewed or approved by the U.S. Food and Drug Administration (FDA) for safety, quality, or efficacy. The FDA does not verify the safety or effectiveness of compounded drugs. These medications may be prescribed when a licensed clinician determines that commercially available, FDA-approved drugs are not medically suitable or are inaccessible for a specific patient.

2. No Medical Advice & No Doctor-Patient Relationship

The information published on this website is designed solely for informational and educational purposes. None of the content provided on this website should be interpreted as medical advice, medical diagnosis, or medical treatment.

Always seek the direct guidance of a qualified physician or other licensed healthcare professional with any questions you may have regarding a medical condition, diet, or prescription medication. Never disregard professional medical advice or delay in seeking it because of something you have read on this site.

Telehealth consultations, evaluations, and any subsequent prescription decisions are handled independently by board-certified healthcare providers affiliated with Gala Health or its medical partner groups (such as OpenLoop-affiliated medical groups). This website does not practice medicine, prescribe medications, or dispense pharmaceutical products.

3. FTC Affiliate & Material Connection Disclosure (16 CFR Part 255)

In compliance with Federal Trade Commission (FTC) guidelines, please be advised that this website operates as an independent review and referral publication that participates in affiliate marketing programs.

We maintain an affiliate relationship with Gala Health (galaglp1.com). If you click on a referral link on this website and subsequently enroll in a telehealth program or purchase a subscription, we may receive financial compensation (an affiliate referral fee or commission) from Gala Health. This referral relationship does not increase the price you pay; you receive the standard or promotional rate offered directly by the provider.

4. Results & Weight Loss Disclaimer

Clinical studies of GLP-1 and dual GLP-1/GIP medications have demonstrated average body weight reductions of 10% to 15% (or more) over a 6-month to 12-month period when combined with reduced-calorie dietary adjustments and physical activity. However, individual results will vary significantly based on starting weight, biological factors, metabolic health, genetics, dosage tolerance, and adherence to lifestyle recommendations.

5. Trademark & Third-Party Brand Notices

Ozempic®, Wegovy®, and Rybelsus® are registered trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company. Any mention of these brand-name products on this website is made strictly for comparative, nominative, and educational purposes to describe active pharmacological classes. Neither this website nor Gala Health is endorsed by, affiliated with, or sponsored by Novo Nordisk or Eli Lilly.

6. Contact & Inquiries

For questions or editorial feedback concerning the medical and affiliate disclosures on this website, please reach out to our compliance desk at: compliance@galaglp1.com.